Amgen Files Lawsuit Against Roche for Patent Infringement
11-Nov-2005
Amgen markets a recombinant human EPO product in the United States as EPOGEN(R) (Epoetin alfa) for the treatment of anemia associated with chronic renal failure for patients on dialysis. Amgen's patent rights on erythropoietin protect Amgen's breakthrough inventions.
Most read news
Topics
Amgen
EPO
patents
Hoffmann-La Roche
Roche Diagnostics
patent infringement
Epogen
dialysis
chronic renal failure
anemia
Organizations
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.